Regeneron Pharmaceuticals discovers and develops pharmaceutical products for treating diseases across multiple therapeutic areas including ophthalmology, immunology, cardiovascular, metabolic, neurological, infectious, and oncology conditions. The company manufactures and markets several approved medications such as EYLEA for retinal diseases, Dupixent for atopic conditions, Libtayo for skin cancer, Praluent for high cholesterol, and Kevzara for rheumatoid arthritis. Through partnerships with companies like Bayer, Alnylam, Intellia, and others, Regeneron is advancing next-generation therapies including RNA interference, gene editing, and radiopharmaceutical approaches.
1Y: 927.89 (+43.1%) · range 599.96–927.89
entry readiness 11 · NOT READY · exit proximity 50
Value area 590.83–783.76 · 0% of 120d volume overhead · clean runway
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.615 | Oct 30, 2026 |
| trend-signal | 0.053 | Oct 30, 2026 |
none
WEAKENING · rank 5 · none
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.72% | -1.72% | 1/20d |
| 40d | -1.72% | -1.72% | 1/40d |